
Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma – Drugs In Development, 2022, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.
Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 29, 12, 1, 23, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 3, 2 and 1 molecules, respectively.
Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma – Drugs In Development, 2022, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.
Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 29, 12, 1, 23, 1 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 3, 2 and 1 molecules, respectively.
Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
212 Pages
- Introduction
- Global Markets Direct Report Coverage
- Uveal Melanoma – Overview
- Uveal Melanoma – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Uveal Melanoma – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Uveal Melanoma – Companies Involved in Therapeutics Development
- A6 Pharmaceuticals LLC
- Acrotech Biopharma LLC
- Adagene Suzhou Ltd
- Aeglea BioTherapeutics Inc
- Alpine Immune Sciences Inc
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- Aura Biosciences Inc
- Bellicum Pharmaceuticals Inc
- Biogazelle NV
- BioMed Valley Discoveries Inc
- Bristol-Myers Squibb Co
- Byondis BV
- Codiak BioSciences Inc
- Delcath Systems Inc
- Dompe Farmaceutici SpA
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Faron Pharmaceuticals Oy
- Foghorn Therapeutics Inc
- Fusion Pharmaceuticals Inc
- GSK plc
- Hillstream BioPharma Inc
- Ideaya Biosciences Inc
- Immunocore Holdings Plc
- Immunocore Limited
- Inventiva SA
- InxMed (Beijing) Co Ltd
- iOnctura SA
- Kezar Life Sciences Inc
- Kymera Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Linnaeus Therapeutics Inc
- Lyvgen Biopharma Ltd
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Modulation Therapeutics Inc
- Novartis AG
- Okogen Inc
- Oncomatryx Biopharma SL
- OncoSpherix Inc
- Ono Pharmaceutical Co Ltd
- Oxular Ltd
- Pfizer Inc
- Plexxikon Inc
- Prelude Therapeutics Inc
- Provectus Biopharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Rubius Therapeutics Inc
- Sapience Therapeutics Inc
- Seagen Inc
- Statera Biopharma Inc
- TriSalus Life Sciences Inc
- Vanquish Oncology Inc
- Verastem Inc
- WPD Pharmaceuticals Inc
- Uveal Melanoma – Drug Profiles
- (nivolumab + relatlimab) – Drug Profile
- ADG-126 – Drug Profile
- Alocelyvir – Drug Profile
- Antisense Oligonucleotides for Oncology – Drug Profile
- belinostat – Drug Profile
- belzupacap sarotalocan – Drug Profile
- bexmarilimab – Drug Profile
- binimetinib – Drug Profile
- BPX-701 – Drug Profile
- cabozantinib s-malate – Drug Profile
- Cell Therapy for Metastatic Uveal Melanoma – Drug Profile
- Cell Therapy to Target GP100 for Melanoma and Non Small Cell Lung Cancer – Drug Profile
- Cellular Immunotherapy for Solid Tumors – Drug Profile
- Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma – Drug Profile
- crizotinib – Drug Profile
- darovasertib – Drug Profile
- davoceticept – Drug Profile
- defactinib hydrochloride – Drug Profile
- Drugs for Uveal Melanoma – Drug Profile
- DYP-688 – Drug Profile
- entolimod – Drug Profile
- entrectinib – Drug Profile
- etigilimab – Drug Profile
- exoASO-STAT6 – Drug Profile
- FHD-286 – Drug Profile
- FPI-1434 – Drug Profile
- gebasaxturev – Drug Profile
- Gene Therapy to Target MAGE-C2 for Oncology – Drug Profile
- ibudilast – Drug Profile
- IMCF-106C – Drug Profile
- IN-10018 – Drug Profile
- IOA-244 – Drug Profile
- ipilimumab – Drug Profile
- ipilimumab + nivolumab – Drug Profile
- KCN-1 – Drug Profile
- KT-253 – Drug Profile
- KZR-261 – Drug Profile
- ladarixin – Drug Profile
- LNS-8801 – Drug Profile
- LVGN-6051 – Drug Profile
- LVGN-7409 – Drug Profile
- melphalan hydrochloride – Drug Profile
- MTI-201 – Drug Profile
- NAV-2729 – Drug Profile
- niraparib – Drug Profile
- nivolumab – Drug Profile
- OMTX-703 – Drug Profile
- OXU-004 SR – Drug Profile
- OXU-005 – Drug Profile
- PAC-1 – Drug Profile
- pegzilarginase – Drug Profile
- PLX-2853 – Drug Profile
- PRT-811 – Drug Profile
- PV-10 – Drug Profile
- RP-2 – Drug Profile
- RTX-240 – Drug Profile
- salinomycin – Drug Profile
- SD-101 – Drug Profile
- SEA-CD40 – Drug Profile
- Small Molecule for Uveal Melanoma – Drug Profile
- Small Molecule to Inhibit HIF-1 and HIF-2 for Uveal Melanoma – Drug Profile
- sotrastaurin acetate – Drug Profile
- SSI-361 – Drug Profile
- ST-101 – Drug Profile
- sunitinib malate – Drug Profile
- SYD-3521 – Drug Profile
- tebentafusp – Drug Profile
- ulixertinib – Drug Profile
- Vaccine for Oncology – Drug Profile
- VS-6766 – Drug Profile
- WPD-102 – Drug Profile
- Yap-Tead – Drug Profile
- YM-254890 – Drug Profile
- ziv-aflibercept – Drug Profile
- Uveal Melanoma – Dormant Projects
- Uveal Melanoma – Discontinued Products
- Uveal Melanoma – Product Development Milestones
- Featured News & Press Releases
- Jun 08, 2022: Medison Pharma announces the approvals by Health Canada and Therapeutics Goods Administration of KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
- Jun 07, 2022: Provectus Biopharmaceuticals announces acceptance of PV-10 immunotherapy abstract for metastatic uveal melanoma at American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
- Jun 07, 2022: Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- Jun 07, 2022: iOnctura to present at ASCO encouraging phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kd inhibitor, IOA-244
- Jun 06, 2022: Positive initial results from CHOPIN Phase 1b Trial, FOCUS trial update and QoL Study presented at the 2022 ASCO Annual Meeting
- Jun 06, 2022: Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 27, 2022: iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma
- May 02, 2022: IDEAYA Biosciences receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the treatment of Uveal Melanoma
- Apr 20, 2022: MediciNova announces publication of MN-166 (ibudilast) data regarding prevention of metastasis in uveal melanoma in Molecular Cancer Research
- Apr 13, 2022: Foghorn Therapeutics presents new preclinical data on novel BRG1/BRM inhibitor FHD-286 at the 2022 AACR Annual Meeting
- Apr 04, 2022: European Commission approves KIMMTRAK (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
- Apr 01, 2022: Foghorn Therapeutics to present preclinical data for FHD-286 at the 2022 AACR Annual Meeting
- Mar 21, 2022: Aura Biosciences announces orphan drug designation granted to AU-011 by European Commission for the treatment of uveal melanoma (includes choroidal melanoma)
- Mar 02, 2022: Hillstream BioPharma R&D day highlights ferroptosis, the non-genetic novel, emerging mechanism of action, targeting drug resistant and devastating cancers
- Feb 26, 2022: Provectus Biopharmaceuticals announces acceptance of PV-10 metastatic uveal melanoma abstract for oral presentation at 2022 International Society of Ocular Oncology (ISOO) Congress
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Uveal Melanoma, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Universities/Institutes, 2022
- Table 6: Products under Development by Companies, 2022
- Table 7: Products under Development by Companies, 2022 (Contd..1)
- Table 8: Products under Development by Companies, 2022 (Contd..2)
- Table 9: Products under Development by Companies, 2022 (Contd..3)
- Table 10: Products under Development by Universities/Institutes, 2022
- Table 11: Number of Products by Stage and Target, 2022
- Table 12: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 13: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 14: Number of Products by Stage and Mechanism of Action, 2022
- Table 15: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 16: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 17: Number of Products by Stage and Route of Administration, 2022
- Table 18: Number of Products by Stage and Molecule Type, 2022
- Table 19: Uveal Melanoma – Pipeline by A6 Pharmaceuticals LLC, 2022
- Table 20: Uveal Melanoma – Pipeline by Acrotech Biopharma LLC, 2022
- Table 21: Uveal Melanoma – Pipeline by Adagene Suzhou Ltd, 2022
- Table 22: Uveal Melanoma – Pipeline by Aeglea BioTherapeutics Inc, 2022
- Table 23: Uveal Melanoma – Pipeline by Alpine Immune Sciences Inc, 2022
- Table 24: Uveal Melanoma – Pipeline by Astellas Pharma Inc, 2022
- Table 25: Uveal Melanoma – Pipeline by Astex Pharmaceuticals Inc, 2022
- Table 26: Uveal Melanoma – Pipeline by Aura Biosciences Inc, 2022
- Table 27: Uveal Melanoma – Pipeline by Bellicum Pharmaceuticals Inc, 2022
- Table 28: Uveal Melanoma – Pipeline by Biogazelle NV, 2022
- Table 29: Uveal Melanoma – Pipeline by BioMed Valley Discoveries Inc, 2022
- Table 30: Uveal Melanoma – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 31: Uveal Melanoma – Pipeline by Byondis BV, 2022
- Table 32: Uveal Melanoma – Pipeline by Codiak BioSciences Inc, 2022
- Table 33: Uveal Melanoma – Pipeline by Delcath Systems Inc, 2022
- Table 34: Uveal Melanoma – Pipeline by Dompe Farmaceutici SpA, 2022
- Table 35: Uveal Melanoma – Pipeline by Exelixis Inc, 2022
- Table 36: Uveal Melanoma – Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Table 37: Uveal Melanoma – Pipeline by Faron Pharmaceuticals Oy, 2022
- Table 38: Uveal Melanoma – Pipeline by Foghorn Therapeutics Inc, 2022
- Table 39: Uveal Melanoma – Pipeline by Fusion Pharmaceuticals Inc, 2022
- Table 40: Uveal Melanoma – Pipeline by GSK plc, 2022
- Table 41: Uveal Melanoma – Pipeline by Hillstream BioPharma Inc, 2022
- Table 42: Uveal Melanoma – Pipeline by Ideaya Biosciences Inc, 2022
- Table 43: Uveal Melanoma – Pipeline by Immunocore Holdings Plc, 2022
- Table 44: Uveal Melanoma – Pipeline by Immunocore Limited, 2022
- Table 45: Uveal Melanoma – Pipeline by Inventiva SA, 2022
- Table 46: Uveal Melanoma – Pipeline by InxMed (Beijing) Co Ltd, 2022
- Table 47: Uveal Melanoma – Pipeline by iOnctura SA, 2022
- Table 48: Uveal Melanoma – Pipeline by Kezar Life Sciences Inc, 2022
- Table 49: Uveal Melanoma – Pipeline by Kymera Therapeutics Inc, 2022
- Table 50: Uveal Melanoma – Pipeline by Kyorin Pharmaceutical Co Ltd, 2022
- Table 51: Uveal Melanoma – Pipeline by Linnaeus Therapeutics Inc, 2022
- Table 52: Uveal Melanoma – Pipeline by Lyvgen Biopharma Ltd, 2022
- Table 53: Uveal Melanoma – Pipeline by Merck & Co Inc, 2022
- Table 54: Uveal Melanoma – Pipeline by Mereo Biopharma Group Plc, 2022
- Table 55: Uveal Melanoma – Pipeline by Modulation Therapeutics Inc, 2022
- Table 56: Uveal Melanoma – Pipeline by Novartis AG, 2022
- Table 57: Uveal Melanoma – Pipeline by Okogen Inc, 2022
- Table 58: Uveal Melanoma – Pipeline by Oncomatryx Biopharma SL, 2022
- Table 59: Uveal Melanoma – Pipeline by OncoSpherix Inc, 2022
- Table 60: Uveal Melanoma – Pipeline by Ono Pharmaceutical Co Ltd, 2022
- Table 61: Uveal Melanoma – Pipeline by Oxular Ltd, 2022
- Table 62: Uveal Melanoma – Pipeline by Pfizer Inc, 2022
- Table 63: Uveal Melanoma – Pipeline by Plexxikon Inc, 2022
- Table 64: Uveal Melanoma – Pipeline by Prelude Therapeutics Inc, 2022
- Table 65: Uveal Melanoma – Pipeline by Provectus Biopharmaceuticals Inc, 2022
- Table 66: Uveal Melanoma – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 67: Uveal Melanoma – Pipeline by Replimune Ltd, 2022
- Table 68: Uveal Melanoma – Pipeline by Rubius Therapeutics Inc, 2022
- Table 69: Uveal Melanoma – Pipeline by Sapience Therapeutics Inc, 2022
- Table 70: Uveal Melanoma – Pipeline by Seagen Inc, 2022
- Table 71: Uveal Melanoma – Pipeline by Statera Biopharma Inc, 2022
- Table 72: Uveal Melanoma – Pipeline by TriSalus Life Sciences Inc, 2022
- Table 73: Uveal Melanoma – Pipeline by Vanquish Oncology Inc, 2022
- Table 74: Uveal Melanoma – Pipeline by Verastem Inc, 2022
- Table 75: Uveal Melanoma – Pipeline by WPD Pharmaceuticals Inc, 2022
- Table 76: Uveal Melanoma – Dormant Projects, 2022
- Table 77: Uveal Melanoma – Dormant Projects, 2022 (Contd..1)
- Table 78: Uveal Melanoma – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Uveal Melanoma, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.